利索-全球专利检索

  1. 登录
  2. 注册
发明公开
CN101054416A HAb18GC2单抗和其轻、重链可变区基因、编码多肽及应用 有权 转让

HAb18GC2单抗和其轻、重链可变区基因、编码多肽及应用
摘要：
本发明涉及单克隆抗体HAb18GC2及其重链和轻链可变区基因、编码的多肽，以及所述单抗、重链和轻链可变区基因和多肽在制备用于逆转肝纤维化等基质沉积疾病的治疗剂中的应用。本发明的单抗HAb18GC2可与人肝纤维化组织中高表达的抗原HAb18G/CD147及肝星状细胞特异性结合；具有促进MMPs分泌，降解细胞外基质的功能。本发明人成功地克隆了该抗体的轻、重链可变区基因。基于上述基因，构建和表达成多种形式的小分子基因工程抗体，制备用于逆转肝纤维化等基质沉积相关疾病的药物。基于上述基因所编码的多肽，可以交联上多种效应分子，制备用于逆转肝纤维化等基质沉积相关疾病的药物。
摘要（英）：

The present invention relates to monoclonal antibody HAb18GC2 and its variable area gene of its heavy chain and light chain and polypeptide, and their uses in preparing therapeutic agent for reversing hepatic fibrosis etc. matrix deposition disease. The present monoclonal antibody HAb18GC2 can bind specificly with antibody HAb18G/CD147 highly expressed in human liver fibrosis tissue and with liver astrocyte and possesses function of facilitating MMPs secretion and reducing the extracellular matrix. The antibody light, heavy chain variable area genes are successfully cloned in the present invention and small molecule gene engineered antibodies of all kinds are constructed and expressed based on the gene for preparing drug for reversing liver fibrosis matrix deposition-related disease. The polypeptide coded by the present gene can crosslink with multiple effector molecule and prepare drug for reversing liver fibrosis matrix deposition-related disease.

公开/授权文献
0/0